Development of Passive Immunotherapies for Synucleinopathies.
about
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.Recent advances in treating Parkinson's disease.Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.Recombinant Antibody Fragments for Neurodegenerative Diseases.Alpha-synuclein and iron: two keys unlocking Parkinson's disease.AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy.Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration.Vaccination strategies in tauopathies and synucleinopathies.Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease.Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
P2860
Q33701172-A3494A9E-FF1F-42E5-8E3E-AF8E3E3C73D0Q33776552-F5B4A801-5FFF-46B6-B7BA-869789443AE1Q34554401-ABD7A0BC-DA98-4BE9-8B1F-8BCD256A0B5CQ38817063-6A8A28DA-72C8-47AD-AAFF-8C16B4476AEBQ38970823-70E98E94-4E84-464E-829F-FF9E7AC9F39DQ39123736-68E24373-AD39-4719-9B78-8E0D526D46F8Q40052760-3328474E-E8BC-40FD-9B73-F8F5CC85C99BQ40968608-0DEA687C-61BA-4D37-BD06-D92CB9511D98Q41126307-DCC35E4E-A902-422E-BABD-89A16F631E04Q46354756-D8701C31-66F1-401C-925C-2D68E81AE428Q47423589-C4420D7B-577A-466C-BA2B-EAE765B01C98Q47860105-7BF89852-B340-4FE6-91F3-8E7251985592Q49987358-65FD6266-FB02-4B19-BBF2-B34534EB5DC2Q52568381-D71B037E-D903-4DCF-9148-4CC5B4F49DB2Q54982491-87353685-9142-439D-AE95-2EB0F6D84C0D
P2860
Development of Passive Immunotherapies for Synucleinopathies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Development of Passive Immunotherapies for Synucleinopathies.
@en
type
label
Development of Passive Immunotherapies for Synucleinopathies.
@en
prefLabel
Development of Passive Immunotherapies for Synucleinopathies.
@en
P2093
P2860
P356
P1433
P1476
Development of Passive Immunotherapies for Synucleinopathies.
@en
P2093
Ann-Louise Bergström
Karina Fog
Pekka Kallunki
P2860
P304
P356
10.1002/MDS.26481
P407
P577
2015-12-25T00:00:00Z